阿加曲班注射液联合依达拉奉治疗急性缺血性脑梗死的临床疗效

目的探讨阿加曲班注射液联合依达拉奉治疗急性缺血性脑梗死的临床疗效。方法选取南京医科大学附属脑科医院2012年7月-2013年6月收治的140例急性缺血性脑梗死患者，分为对照组（68例）和治疗组（72例）。两组患者均给予依达拉奉注射液30mg／次，溶于100mL生理盐水30min内滴完，2次／d。在对照组基础上，治疗组前两天给予阿加曲班注射液60mg／d，溶于48mL生理盐水24h静脉滴注，其后给予阿加曲班注射液10mg／d，溶于250mL生理盐水，分早晚2次持续滴注，3ll／次，共用药7d，两组均治疗14d。比较两组的血液流变学指标、血凝指标和生活质量各项指标。结果治疗后两组各项血液流变学指标均低于治疗前，差异有统计学意义（P〈0．05）；且治疗组各项血液流变学指标均低于对照组，差异有统计学意义（P〈0．05）。治疗后两组的血凝指标和生活质量各项指标均较治疗前有所改善，且治疗组优于对照组，差异有统计学意义（P〈0．05）。结论阿加曲班注射液联合依达拉奉治疗急性缺血性脑梗死具有显著效果，值得临床推广。

Clinical efficacy of Argatroban Injection combined with edaravone in treatment of acute ischemic cerebral infarction

Objective To explore the clinical efficacy of Argatroban Injection combined with edaravone in the treatment of acute ischemic cerebral infarction. Methods Patients （140 cases） with acute ischemic cerebral infarction, who came to Affiliated Nanjing Brain Hospital, Nanjing Medical University, from July 2012 to June 2013, were divided into control group （68 cases） and treatment group （72 cases）. Patients in the two groups were given Edaravone Injection 30 mg/time, which was dissolved in saline 100 mL and was dripped completely within 30 min, twice daily. On the basis of the control group, patients in the treatment group were given Argatroban Injection 60 mg/d, which was dissolved in saline 48 mL and was iv completely within 24 h on two days before. And then they were given Argatroban Injection 10 mg/d, which was dissolved in saline 250 mL and was continuously dripped twice in the morning and evening, 3 h/time, for 7 d. The patients accepted the treatment for 14 d. The hemodynamics, blood coagulation, and quality of life indexes in the two groups were compared. Results After the treatment, the hemodynamic indexes in the two groups were lower than those before the treatment with significant difference （P 〈 0.05）. And the hemodynamic indexes in the treatment group were lower than those in the control group with significant difference （P 〈 0.05）. After the treatment, the blood coagulation and quality of life indexes in the two groups were improved compared with those before the treatment. And the blood coagulation and quality of life indexes in the treatment group were better than those in the control group with significant difference （P 〈 0.05）. Conclusion Argatroban Injection combined with edaravone in the treatment of acute ischemic cerebral infarction has a good clinical efficacy, which is worthy of clinical application.